Vericel Co. (NASDAQ:VCEL) CEO Dominick Colangelo Sells 17,500 Shares

Vericel Co. (NASDAQ:VCEL) CEO Dominick Colangelo sold 17,500 shares of the firm’s stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $44.59, for a total transaction of $780,325.00. Following the completion of the sale, the chief executive officer now owns 195,307 shares in the company, valued at $8,708,739.13. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Dominick Colangelo also recently made the following trade(s):

• On Wednesday, March 13th, Dominick Colangelo sold 17,500 shares of Vericel stock. The shares were sold at an average price of $44.67, for a total transaction of $781,725.00.

Vericel Stock Down 0.3 %

Shares of NASDAQ:VCEL opened at $43.74 on Friday. The firm has a market cap of $2.12 billion, a P/E ratio of -485.95 and a beta of 1.71. Vericel Co. has a 12-month low of $29.24 and a 12-month high of $53.05. The business has a fifty day simple moving average of $47.58 and a 200 day simple moving average of $40.42.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings data on Thursday, February 29th. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.08. Vericel had a negative return on equity of 1.55% and a negative net margin of 1.61%. The company had revenue of $65.00 million during the quarter, compared to the consensus estimate of $64.28 million. During the same period last year, the company earned $0.12 earnings per share. The firm’s revenue was up 23.3% compared to the same quarter last year. As a group, equities research analysts expect that Vericel Co. will post 0.09 EPS for the current year.

Institutional Investors Weigh In On Vericel

A number of institutional investors have recently modified their holdings of VCEL. MCF Advisors LLC raised its stake in Vericel by 86.1% during the first quarter. MCF Advisors LLC now owns 482 shares of the biotechnology company’s stock worth $25,000 after buying an additional 223 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new position in shares of Vericel in the 4th quarter worth about $33,000. Tower Research Capital LLC TRC lifted its stake in shares of Vericel by 174.3% in the 1st quarter. Tower Research Capital LLC TRC now owns 1,668 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 1,060 shares during the period. GAMMA Investing LLC bought a new stake in shares of Vericel during the 4th quarter valued at about $65,000. Finally, Shell Asset Management Co. bought a new stake in shares of Vericel during the 4th quarter valued at about $74,000.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. HC Wainwright upped their price target on shares of Vericel from $46.00 to $53.00 and gave the stock a “buy” rating in a report on Friday, March 1st. TheStreet upgraded Vericel from a “d+” rating to a “c-” rating in a research report on Monday, January 29th. Finally, Truist Financial reiterated a “buy” rating and issued a $54.00 target price on shares of Vericel in a research report on Tuesday, March 26th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Vericel presently has an average rating of “Moderate Buy” and an average target price of $46.40.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.